Table 3.

Factors influencing tocilizumab effectiveness in 3 assessment methods: DAS28-ESR remission, EULAR Good Response, and Boolean remission (a full-model multivariate logistic regression analysis). Shaded factors have been shown to support the achievement of DAS28-ESR remission, EULAR Good Response, and Boolean-based remission.

		DAS28-ESR Remission		EULAR Good Response		Boolean Remission
		OR (95% CI)	p	OR (95% CI)	p	OR (95% CI)	p
Sex	Female vs male	0.74 (0.625–0.877)	0.0005	0.856 (0.725–1.012)	0.0681	1.047 (0.841–1.303)	0.6825
Age	Per 10-yr increase	0.874 (0.829–0.921)	< 0.0001	0.896 (0.851–0.944)	< 0.0001	0.957 (0.897–1.022)	0.1933
Body weight	≥ 40 vs < 40 kg	1.360 (1.006–1.838)	0.0453	1.347 (1.019–1.780)	0.0363	1.801 (1.089–2.978)	0.0219
Duration of disease	2–10 vs < 2 yrs	0.974 (0.795–1.194)	0.8008	0.847 (0.690–1.040)	0.1136	0.935 (0.737–1.185)	0.5785
Duration of disease	≥ 10 vs < 2 yrs	0.847 (0.673–1.066)	0.1562	0.747 (0.594–0.940)	0.0127	0.610 (0.458–0.814)	0.0008
Steinbrocker stage	III + IV vs I + II	0.722 (0.615–0.847)	< 0.0001	0.771 (0.658–0.903)	0.0013	0.736 (0.601–0.901)	0.0030
Steinbrocker class	3 + 4 vs 1 + 2	0.652 (0.557–0.765)	< 0.0001	0.709 (0.611–0.823)	< 0.0001	0.630 (0.490–0.809)	0.0003
Previous use of biologics	1 agent vs none	0.621 (0.537–0.719)	< 0.0001	0.669 (0.579–0.774)	< 0.0001	0.615 (0.512–0.739)	< 0.0001
Previous use of biologics	2 agents vs none	0.494 (0.409–0.596)	< 0.0001	0.566 (0.472–0.679)	< 0.0001	0.407 (0.310–0.536)	< 0.0001
MTX use (concomitant drug^a)	Present vs absent	1.158 (1.013–1.323)	0.0314	1.148 (1.008–1.308)	0.0372	0.903 (0.759–1.075)	0.2507
Corticosteroid use (concomitant drug^a)	0–5 mg/day^b vs none	0.815 (0.697–0.952)	0.0099	0.932 (0.798–1.088)	0.3702	0.679 (0.562–0.819)	< 0.0001
Corticosteroid use (concomitant drug^a)	> 5 mg/day^b vs none	0.564 (0.470–0.678)	< 0.0001	0.641 (0.536–0.766)	< 0.0001	0.412 (0.320–0.530)	< 0.0001
NSAID use (concomitant drug^a)	Present vs absent	0.865 (0.757–0.988)	0.0325	0.786 (0.689–0.896)	0.0003	0.692 (0.584–0.820)	< 0.0001
DAS28-ESR (at baseline)	Per 1-pt increase	0.628 (0.595–0.663)	< 0.0001	0.794 (0.755–0.835)	< 0.0001	0.745 (0.696–0.796)	< 0.0001

↵a Concomitant use at any timepoint during the observation period, including baseline.
↵b Dose is prednisolone equivalent. DAS28-ESR: Disease Activity Score based on 28-joint-erythrocyte sedimentation rate; EULAR: European League Against Rheumatism; MTX: methotrexate; NSAID: nonsteroidal antiinflammatory drug.